Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Patel A, Hissong E, Rosado L, Burkhardt R, Cong L, Alperstein SA, et al. Next-Generation Sequencing of Cell-Free DNA Extracted From Pleural Effusion Supernatant: Applications and Challenges. Front Med (Lausanne). 2021;8:662312.

Singh AK, Haque M, O'Sullivan K, Chourasia M, Ouseph MM, Ahmed S. Suppression of monosodium urate crystal-induced inflammation by inhibiting TGF-β-activated kinase 1-dependent signaling: role of the ubiquitin proteasome system. Cell Mol Immunol. 2021;18(1):162-170.

Rendeiro AF, Ravichandran H, Bram Y, Chandar V, Kim J, Meydan C, et al. The spatial landscape of lung pathology during COVID-19 progression. Nature. 2021;593(7860):564-569.

Centenera MM, Scott JS, Machiels J, Nassar ZD, Miller DC, Zinonos I, et al. ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer. Cancer Res. 2021;81(7):1704-1718.

Gill CM, Aktaş E, Alfouzan W, Bourassa L, Brink A, Burnham C-, et al. Elevated MICs of Susceptible Antipseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa: Implications for Dose Optimization. Antimicrob Agents Chemother. 2021;65(11):e0120421.

Wang L, Liu D, Yung L, Rodriguez GD, Prasad N, Segal-Maurer S, et al. Co-Infection with 4 Species of Mycobacteria Identified by Using Next-Generation Sequencing. Emerg Infect Dis. 2021;27(11):2948-2950.

Sparano JA, Lee JY, Kaplan LD, Ramos JC, Ambinder RF, Wachsman W, et al. Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma. Haematologica. 2021;106(3):730-735.

Fragliasso V, Tameni A, Inghirami G, Mularoni V, Ciarrocchi A. Cytoskeleton Dynamics in Peripheral T Cell Lymphomas: An Intricate Network Sustaining Lymphomagenesis. Front Oncol. 2021;11:643620.

Manning DK, Shivdasani P, Koeller DR, Schwartz A, Rana HQ, Garber JE, et al. Assessment of genomic alterations in non-syndromic von Hippel-Lindau: Insight from integrating somatic and germline next generation sequencing genomic data. Data Brief. 2021;39:107653.

Moskowitz AJ, Ghione P, Jacobsen E, Ruan J, Schatz JH, Noor S, et al. A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas. Blood. 2021;138(26):2828-2837.